$GUTS

FRACTYL HEALTH, INC. (GUTS): Submission of Matters to a Vote of Security Holders

FRACTYL HEALTH, INC. (GUTS) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K 0001572616 false 0001572616 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10,

Original reporting
Published Jun 11, 2026, 9:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 11, 2026, 9:16 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$GUTS
Neutral
high confidence
Mentioned
$GUTS
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$GUTSNeutralLow
01

Why it matters

Board members were elected and the independent auditor appointment was ratified; no new operating or financial commitments were announced.

02

Market read

Primarily governance housekeeping; traders may treat as low-catalyst unless they are tracking proxy/activism narratives.

03

What to watch

Broker non-votes and withheld votes are disclosed, but the article does not provide context (e.g., activist campaign, proxy contest) that would typically drive a tradable catalyst.

Relevance 6/10Novelty 3/10Timing: after-hours/filing day (2026-06-11)

Background

The company filed an SEC 8-K item summarizing matters voted on at its June 10, 2026 annual meeting.

Company-level read

Ticker impact

$GUTSNeutralHigh confidence
Context

Fractyl Health reported 2026 annual meeting voting results, including election of directors and ratification of Ernst & Young as auditor.

Expected impact

Low near-term impact; any reaction is likely sentiment/technical rather than fundamentals.

Evidence & confidence

The filing discloses vote tallies for routine items (director election and auditor ratification) without new financial guidance, deals, or regulatory outcomes.

Market effects

Minimal; no sector-wide regulatory/clinical/financing signal is disclosed.

None indicated.

None indicated.

Counterpoint

If the vote tallies imply contested governance (high withheld/broker non-vote), traders could watch for follow-on activism or proxy disputes, but the filing itself doesn’t indicate a dispute outcome beyond election/approval.

Key entities

  • Fractyl Health, Inc.

    Nasdaq-listed company filing the 8-K with annual meeting voting results.

  • Ernst & Young LLP

    Independent registered public accounting firm ratified for fiscal year ending Dec. 31, 2026.

Related articles

MedAI 8/10

Fractyl Health Helps Maintain Weight After Stopping Popular Obesity Drugs, Stock Soars - Fractyl Health (

Fractyl Health reported one-year results for its Revita procedure in a 45-participant modified intention-to-treat group. Revita cut weight regain versus sham, with least-squares mean regain of 7.8% vs 13.0%. In higher-intensity duodenal ablation subgroups, it preserved about 81% to 84% of GLP-1 weight loss. Safety was similar between groups. Shares rose 19.54% to $0.85.

$GUTSMed

Fractyl's Revita Maintains Weight Loss Post GLP-1 Discontinuation; Stock Up

Fractyl Health (GUTS) reported one-year randomized REMAIN-1 midpoint cohort results for its Revita duodenal mucosal resurfacing system in patients who stopped GLP-1 therapy. In 45 participants, Revita cut weight regain versus sham (7.8% vs 13.0% of body weight). Responder rates were 73% vs sham, rising to 91% with complete ablation. Stock rose to $0.80.

$GUTSMedAI 8/10

Fractyl Health Reports Positive Randomized Data from REMAIN-1 Midpoint Cohort Demonstrating Durable Weight Maintenance One Year After GLP-1 Discontinuation

Fractyl Health (Nasdaq: GUTS) reported one-year, randomized sham-controlled REMAIN-1 midpoint cohort results for its Revita DMR system after GLP-1 discontinuation. In mITT (N=45), weight regain was 7.8% vs 13.0% with sham. Complete duodenal ablation (>14 cm) retained ~81% vs 48% with sham. No device-related serious AEs. Next: six-month pivotal topline in early Q4 2026 and possible FDA De Novo late Q4 2026.

$SKHYMed

SK Hynix’s $38 billion buildout has a name attached: Nvidia

SK Hynix (SKHY) approved about 54.3 trillion won (about $38.3B) for two memory plants through 2031, Reuters reported. About 35.2 trillion won funds a DRAM fab in Yongin (Y2) with construction starting July 2027 and first cleanroom June 2029. Remaining 19.1 trillion won supports a NAND plant in Cheongju. Reuters also said it is reviewing further shareholder returns.

$ITWMed

Illinois Tool Works Authorizes $6 Bln Buyback

Illinois Tool Works (ITW) said its board authorized a new share repurchase program of up to $6 billion. The board also approved a 7% increase in its regular annual cash dividend to $6.88 per share, effective with the Q4 dividend of $1.72 payable Oct. 9, 2026. ITW closed at $296.66 on Friday.

$JNJMed

Money talcs: Why J&J offered $5.5bn to end cancer cases

Johnson & Johnson is offering $5.5 billion to settle most of more than 70,000 pending talc-related cancer lawsuits, according to the company. Claims allege ovarian cancer or mesothelioma linked to asbestos-contaminated talc. J&J denies wrongdoing and says cases lack merit. Prior orders include $966m (LA) and $1.5bn (Baltimore), with appeals planned.